, lack of response to cytoreduction with conventional dose treatment should not preclude ABMT in these patients. Although complete responses are more frequent in chemotherapy-senstive patients a proportion of patients refractory to conventional dose chemotherapy do appear to achieve prolonged CR with highdose therapy, which, in these patients, appears to be the only potentally curative treatment option. Recent studis suggest that patients with poor-prognosis HD may be defined ab inito (Strauss et al., 1990; Proctor et al., 1992) . It has been suged that such patients may be candidates for HDC-ABMT as consolidation treatment (Carella et al., 1991b) . It should, however, be pointed out that by selecting patients who have achieved complete remission (CR) with conventional dose therapy for consolidation with HD-ABMT a different prognostic group is being studied. If HDC-ABMT has a role in poor-prognosis HD it will be best defined by using such therapy as first-line treatment.
We report here a study of 48 patients in whom HDC-ABMT was used as the first-line treatment approach for relapsed or antifungal therapy was utilised as indicated for neutropenic sepsis.
Response criteria All patients were restaged 3 months after transplantation, and standard criteria to assess response were utilised.
Statistical analysis
Response, toxic death, overall survival from date of transplantation and event-free survival were analysed using SAS statistical software. Factors which were examined for influence on response rate included sex, histological subtype, presence or absence of systemic symptoms, haemoglobin concentration, lymphocyte count, number of extranodal sites, presence or absence of marrow involvement, disease bulk, number of relapses, relapse status (relapsed versus refractory disease), the presence of liver involvement and performance status. Survival curves were estimated using the method of Kaplan and Meier, and were compared using the log-rank statistic. (Table V) . The one exception was a patient who died at day 10 post chemotherapy from multiorgan failure related to chemotherapy drug toxicity. This patient was classified as non-evaluable for haematological recovery because of early death.
One patient who was transplanted with extensive disease and a performance status of 3 died of early complications prior to haematological recovery. No other procedure-related mortality was experienced. Two patients had moderate reversible renal toxicity and one patient had a minor intracerebral haemorrhage, from which he made a full recovery (Table  V) .
All patients experienced severe grade 3-4 mucositis, which was usually the major cause of readmission to hospital. This necessitated the use of both intravenous analgesia and fluid for 3-4 days, and occasionally the use of hyperalimentation.
All patients experienced grade 4 neutropenia and thrombocytopenia. The mean time to neutrophil count recovery () 1 x 109) was 23 ± 7 days (range 13-42 days) and the mean time to platelet recovery () 40 x 109) was 27 ± 9 days (range 15-60 days). All patients developed neutropenic fever requiring broad-spectrum intravenous antibiotics.
Survival
The median survival has yet to be reached. Actuarial survival is shown in Figure 1 . Factors analysed for influence on Although the management of Hodgkin's lymphoma has achieved substantial success, with the majority of patients, including even those with extensive disease, attaining durable complete responses using conventional dose combination chemotherapy, there remains a significant proportion of patients who are either refractory to induction therapy or who relapse soon after achieving response. In addition, recent studies suggest that patients who have a poor prognosis with conventional dose chemotherapy (Fisher et al., 1979) may be defined by prognostic criteria which include not only stage but also non-stage-related factors such as histological subtype, age, disease bulk, haemoglobin level and total lymphocyte count (Proctor et al., 1992) . Non-cross-resistant multidrug chemotherapy regimens offer some hope of salvage in these patients, but the long-term disease-free remission and ultimate cure rates remain low. The most promising results have been obtained with the use of high-dose chemotherapy conditionig regmens with autologous bone marrow rescue (HDC-ABMT). Such poorprognosis patients may well be candidates for early HDC-ABMT. Early reports, even in patients with refractory disease, suggested that complete response (CR) rates in excess of 50% could be achieved (Carella et al., 1985) . Although toxic death rates were fairly high in initial studies (3-80%) (Lu et al., 1983; Goldstone et al., 1985) , this could probably be attributed to the fact that the majority of the reported patients had been extensively pretreated and were largely in resistant relapse. In addition, many patients had been previously exposed to thoracic radiotherapy and/or to other agents causing pulmonary toxicity. Such patients have a significantly increased risk of developing respiratory failure due to infection and pulmonary alveolar haemorrhage (JulesElysee et al., 1992) .
More recent studies such as that from Chopra et al. (1993) using a combination of BCNU, etoposide, cytosine arabinoside and melphalan (BEAM) have reported improved results with an approximately 10% prevalence of toxic death and a 50% actuarial 5-year relapse-free survival. Interestingly, these investigators reported a poorer survival not only in patients with refractory disease, but also those in first relapse, with patients in second and third relapse having a superior relapse-free survival.
HDC-ABMT appears to be relatively well tolerated, with good quality of life being attained, especially in responding patients (Chao et al., 1992) . Indeed, 96% of patients indicate that they would be willing to undergo the procedure a second time if necessary (Vose et al., 1992) .
To a large extent, HDC-ABMT procedures have utilised BCV-or BEAM-like regimens given over a number of days and necessitating cryopreservation of the autologous marrow (Reece et al., 1991) . Optimum treatment regimens and schedules remain to be defmed however. Treatment programmes utilising agents such as melphalan and etoposide, which have short half-lives, can be administerd in less than 24 h with the potential advantage of not requiring cryopreservation of marrow (Carella et al., 1985; Taylor et al., 1993) , thus making the procedure less costly and technically less demanding.
There is also controversy as to whether HDC-ABMT should be used as the initial treatment approach for relapsed and refractory disease, or whether cytoreductive therapy should be attempted prior to ABMT. An advantage of initial cytoreduction is that chemosensitivity can be assd prior to transplantation. Numerous investigators have found sensitive relapse to be predictive of remission rate and longer disease-free survival following HDC-ABMT (Crump et al., 1993b) . However, if the approach is to be HDC-ABMT whatever the outcome of cytoreductive therapy, an obvious disadvantage of attempting retreatment prior to HDC-ABMT would be a more heavily pretreated patient undergoing ABMT, with a resultant increase in morbidity and possibly mortality.
The regimen that we have utilised has a number of advantages. No speciaised marrow handling equipment, cryopreservation or storage techniques are required, as the marrow is merely stored at 4-C and reinfused 36-48 h after harvesting. The chemotherapy regimen is uncomplicated and can be administered in a single day, thus allowing the discharge of the patient for 4-7 days prior to the onset of mucositis and neutropenia, with resultant cost savings.
Although morbidity from severe mucositis was high, occurring in all patients, it generally necessitated an inpatient stay of between 7 and 14 days only, and was easily managed. Only one early death occurred, and other morbidity was generally self-limiting.
Whether the use of bone marrow culture with interferon alpha added anything to the treatment of patients with marrow involvement at the time of BMT cannot be determined from the current study. The presence of marrow involvement is obviously a worrying feature with the possibility of returning a contaminated graft. Other possible methods of dealing with this problem may be some positive sekction procedure, selecting for multipotent (stem cell) bone marrow precursors only. However, the utility of and even theoretical background for such procedures must wait for a clearer definition of the characteristics of the malignant cell in HD.
One further aspect that deserves comment is the question of the use of bone marrow as against peripheral blood precursor cells (PBPCs) for effecting haematological rescue.
A number of studies have shown rapid haematological recovery following HDC with growth factor-mobilsed PBPCs in a variety of haematological and non-haematological malignancies Crump et al., 1993a; Pettengel et al., 1993a, b) . The studies of Pettengel et al. suggest more rapid haematological engraftment with PBPCs, but whether BMT or PBPCs is the most cost-effective rescue procedure in patients with HD requires further study.
Despite these provisos it should, however, be pointed out that a 90% complete response rate was achieved and median survival and median time to treatment failure have yet to be reached. Whie a poor performance status and hepatic involvement appeared to be adverse prognostic factors for response, a number of patients with these features did achieve CR and substantial disease-free survival. Relapse status at time of transplant, whether first, second or third relapse, did not appear to affect either response rates or survival.
The regimen and therapeutic approach described appears to offer response rates and survival at least equivalent to those reported in the literature, and is in addition brief and uncomplicated, requiring little speialised equipment and a shortened inpatient hospital stay. There appears to be no advantage to initial cytoreductive therapy in patients with Hodgkin's disease who require ABMT and high-dose chemotherapy, except in patients who require urgent therapy for obstructive complications.
